Literature DB >> 19410386

Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.

Siavash Jabbari1, David Andolino, Vivian Weinberg, Brian T Missett, Jason Law, William M Wara, Richard J O'Donnell, Katherine K Matthay, Steven G DuBois, Robert Goldsby, Daphne A Haas-Kogan.   

Abstract

PURPOSE: To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids. METHODS AND MATERIALS: Twenty-one children diagnosed between 1987 and 2005 were identified. Median age at start of treatment was 13 years (range, 2-21). Primary therapy consisted of resection alone (10), resection + external beam radiation therapy (EBRT) (5), resection + chemotherapy (CT; 3), EBRT alone (1), and CT alone (2).
RESULTS: The median follow-up from start of treatment is 75.7 months (range, 16-162). Examining patients with gross total resections (GTRs) (-) margins and those who had GTRs (+) margins followed by EBRT, only 2 of 7 failed primary treatment. Conversely, 13 of 14 patients with other primary treatments failed locally. Of the 15 patients who recurred, only 1 patient had a GTR (-) margins. Seven of these patients had salvage therapy that did not include RT, and of these only 2 have no evidence of disease (NED) at last follow-up. In contrast, the remaining 8 patients received RT as a component of their final salvage therapy and 7 of these are NED at last follow-up. At last follow-up, no patient has died, although toxicities of therapy have occurred.
CONCLUSIONS: Local control is difficult to achieve in pediatric patients with desmoids. In the setting in which negative surgical margins cannot be achieved, RT plays a key role in achieving NED status. Even after multiple recurrences, successful salvage is achievable, particularly when high-dose focal therapy is incorporated.

Entities:  

Mesh:

Year:  2009        PMID: 19410386     DOI: 10.1016/j.ijrobp.2008.10.072

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  The Role of Pharmacotherapeutic Agents in Children with Desmoid Tumors.

Authors:  David P Douglass; Fariba Navid; Aaron R Weiss
Journal:  Paediatr Drugs       Date:  2022-07-29       Impact factor: 3.930

2.  Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Authors:  Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2012-12-31       Impact factor: 3.167

Review 3.  Advances in therapy for pediatric sarcomas.

Authors:  Aaron Weiss; Jonathan Gill; John Goldberg; Joanne Lagmay; Holly Spraker-Perlman; Rajkumar Venkatramani; Damon Reed
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 4.  The Role of Radiation Therapy for Symptomatic Desmoid Tumors.

Authors:  Wen Shen Looi; Daniel J Indelicato; Michael S Rutenberg
Journal:  Curr Treat Options Oncol       Date:  2021-03-01

5.  Desmoid fibromatosis in pediatric patients: management based on a retrospective analysis of 59 patients and a review of the literature.

Authors:  Caroline Oudot; Daniel Orbach; Véronique Minard-Colin; Jean Michon; Pierre Mary; Christophe Glorion; Sylvie Helfre; Jean-Louis Habrand; Odile Oberlin
Journal:  Sarcoma       Date:  2012-08-05

6.  Recurrent desmoid tumor of the buttock in a preadolescent child.

Authors:  Yogesh Kumar Sarin
Journal:  APSP J Case Rep       Date:  2012-03-01

7.  Desmoid tumors in the pediatric population.

Authors:  Joshua N Honeyman; Michael P La Quaglia
Journal:  Cancers (Basel)       Date:  2012-03-09       Impact factor: 6.639

Review 8.  Desmoid-type fibromatosis of the head and neck in children: a case report and review of the literature.

Authors:  Hidetaka Miyashita; Seiji Asoda; Tomoya Soma; Kanako Munakata; Masaki Yazawa; Taneaki Nakagawa; Hiromasa Kawana
Journal:  J Med Case Rep       Date:  2016-06-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.